BACKGROUND/AIM: New generation androgen receptor-targeting agents (ARTA) have been in the spotlight for their efficacy in metastatic castration-resistant prostate cancer (mCRPC). Prostate-specific antigen (PSA) represents one of the most commonly used serum cancer biomarkers worldwide. The present retrospective study focused on the prognostic role of serum PSA isoforms and their early dynamics in mCRPC patients treated with abiraterone acetate (ABI) or enzalutamide (ENZ). PATIENTS AND METHODS: The association between outcomes of 334 mCRPC patients treated with ABI or ENZ and the levels of serum total PSA (tPSA), free PSA (fPSA), [-2]proPSA and the Prostate Health Index (PHI) at baseline and one month after treatment initiation was analyzed retrospectively. RESULTS: In the multivariable Cox proportional hazards models, baseline tPSA>50 μg/l (p<0.001), and [-2]proPSA>300 ng/l (p=0.017) remained independent significant factors associated with inferior OS, while baseline fPSA>1.75 μg/l (p=0.050) and Δ [-2]proPSA >-50% approached statistical significance (p=0.062). The results of ROC analyses assessing the ability of baseline tPSA, fPSA, and [-2]proPSA to predict mortality within two years showed area under the curve (AUC) values of 0.709, 0.685, and 0.740, respectively. Among the subgroup with baseline tPSA≤20.0 μg/l, the results of ROC analyses for baseline tPSA, fPSA and [-2]proPSA showed AUC values of 0.441, 0.682, and 0.688, respectively. CONCLUSION: Our results suggest a significant correlation between pretreatment serum levels of tPSA and [-2]proPSA with OS in mCRPC patients receiving ARTA.

Biomedical Center Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic

Department of Immunochemistry Diagnostics University Hospital in Pilsen Charles University Pilsen Czech Republic

Department of Oncology and Radiotherapeutics Faculty of Medicine and University Hospital in Pilsen Charles University Pilsen Czech Republic

Department of Oncology and Radiotherapeutics Faculty of Medicine and University Hospital in Pilsen Charles University Pilsen Czech Republic;

Department of Pharmacology Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic

Department of Urology Faculty of Medicine and University Hospital in Pilsen Charles University Pilsen Czech Republic

Institute of Radiation Oncology Bulovka University Hospital and 1 Medical Faculty Charles University Prague Czech Republic

Oncology Ambulance Karlovy Vary Regional Hospital Karlovy Vary Czech Republic

See more in PubMed

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29. doi: 10.3322/caac.21254. PubMed DOI

Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol. 2020;77(1):38–52. doi: 10.1016/j.eururo.2019.08.005. PubMed DOI

Lilja H, Christensson A, Dahlén U, Matikainen MT, Nilsson O, Pettersson K, Lövgren T. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem. 1991;37(9):1618–1625. PubMed

Mikolajczyk SD, Marks LS, Partin AW, Rittenhouse HG. Free prostate-specific antigen in serum is becoming more complex. Urology. 2002;59(6):797–802. doi: 10.1016/s0090-4295(01)01605-3. PubMed DOI

Heidegger I, Klocker H, Pichler R, Horninger W, Bektic J. PSA isoforms’ velocities for early diagnosis of prostate cancer. Anticancer Res. 2015;35(6):3567–3570. PubMed

Stephan C, Jung K, Semjonow A, Schulze-Forster K, Cammann H, Hu X, Meyer HA, Bögemann M, Miller K, Friedersdorff F. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [−2]proprostate-specific antigen-based prostate health index for detection of prostate cancer. Clin Chem. 2013;59(1):280–288. doi: 10.1373/clinchem.2012.195560. PubMed DOI

Lazzeri M, Haese A, Abrate A, de la Taille A, Redorta JP, McNicholas T, Lughezzani G, Lista G, Larcher A, Bini V, Cestari A, Buffi N, Graefen M, Bosset O, Le Corvoisier P, Breda A, de la Torre P, Fowler L, Roux J, Guazzoni G. Clinical performance of serum prostate‐specific antigen isoform [‐2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project. BJU Int. 2013;112(3):313–321. doi: 10.1111/bju.12217. PubMed DOI

Kostos L, Tran B, Azad AA. Combination of PARP inhibitors and androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer. Drugs. 2024;84(9):1093–1109. doi: 10.1007/s40265-024-02071-y. PubMed DOI PMC

Thapa B, De Sarkar N, Giri S, Sharma K, Kim M, Kilari D. Integrating PARP inhibitors in mCRPC therapy: current strategies and emerging trends. Cancer Manag Res. 2024;16:1267–1283. doi: 10.2147/CMAR.S411023. PubMed DOI PMC

Miyazawa Y, Hori K, Tsuji Y, Sekine Y, Arai S, Fujizuka Y, Nomura M, Koike H, Matsui H, Suzuki K. The utility of the [−2]pro‐prostate‐specific antigen level as a prognostic marker in patients with castration‐resistant prostate cancer treated with enzalutamide. Int J Urol. 2023;30(10):839–846. doi: 10.1111/iju.15212. PubMed DOI

Halabi S, Lin CY, Small EJ, Armstrong AJ, Kaplan EB, Petrylak D, Sternberg CN, Shen L, Oudard S, de Bono J, Sartor O. Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. J Natl Cancer Inst. 2013;105(22):1729–1737. doi: 10.1093/jnci/djt280. PubMed DOI PMC

Halabi S, Lin CY, Kelly WK, Fizazi KS, Moul JW, Kaplan EB, Morris MJ, Small EJ. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2014;32(7):671–677. doi: 10.1200/JCO.2013.52.3696. PubMed DOI PMC

Pitcher B, Khoja L, Hamilton RJ, Abdallah K, Pintilie M, Joshua AM. Assessment of a prognostic model, PSA metrics and toxicities in metastatic castrate resistant prostate cancer using data from Project Data Sphere (PDS) PLoS One. 2017;12(2):e0170544. doi: 10.1371/journal.pone.0170544. PubMed DOI PMC

Verzoni E, De Giorgi U, Derosa L, Caffo O, Boccardo F, Facchini G, Porcu L, De Vincenzo F, Zaniboni A, Chiuri VE, Fratino L, Santini D, Adamo V, De Vivo R, Dinota A, Messina C, Ricotta R, Caserta C, Scavelli C, Susi M, Tartarone A, Surace G, Mosca A, Bruno M, Barni S, Grassi P, Procopio G. Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study. Oncotarget. 2016;7(26):40085–40094. doi: 10.18632/oncotarget.9485. PubMed DOI PMC

Schlack K, Krabbe LM, Fobker M, Schrader AJ, Semjonow A, Boegemann M. Early prediction of therapy response to abiraterone acetate using PSA subforms in patients with castration resistant prostate cancer. Int J Mol Sci. 2016;17(9):1520. doi: 10.3390/ijms17091520. PubMed DOI PMC

Facchini G, Caffo O, Ortega C, D’Aniello C, Di Napoli M, Cecere SC, Della Pepa C, Crispo A, Maines F, Ruatta F, Iovane G, Pisconti S, Montella M, Berretta M, Pignata S, Cavaliere C. Very early PSA response to abiraterone in mCRPC patients: a novel prognostic factor predicting overall survival. Front Pharmacol. 2016;7:123. doi: 10.3389/fphar.2016.00123. PubMed DOI PMC

Halabi S, Armstrong AJ, Sartor O, de Bono J, Kaplan E, Lin CY, Solomon NC, Small EJ. Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy. J Clin Oncol. 2013;31(31):3944–3950. doi: 10.1200/JCO.2013.50.3201. PubMed DOI PMC

Hung SC, Wang SS, Li JR, Chen MC, Yang CK, Chen CS, Ho HC, Chiu KY, Cheng CL, Chang CH, Ou YC. Outcome of patients with metastatic castration-resistant prostate cancer after PSA progression with abiraterone acetate. Anticancer Res. 2018;38(9):5429–5436. doi: 10.21873/anticanres.12874. PubMed DOI

Nagata Y, Matsukawa T, Tomisaki I, Fujimoto N. Prostate-specific antigen kinetics during androgen-deprivation therapy predict response to enzalutamide in metastatic castration-resistant prostate cancer. Anticancer Res. 2023;43(1):429–436. doi: 10.21873/anticanres.16178. PubMed DOI

Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE, COU-AA-302 Investigators Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152–160. doi: 10.1016/S1470-2045(14)71205-7. PubMed DOI

Logothetis CJ, Basch E, Molina A, Fizazi K, North SA, Chi KN, Jones RJ, Goodman OB, Mainwaring PN, Sternberg CN, Efstathiou E, Gagnon DD, Rothman M, Hao Y, Liu CS, Kheoh TS, Haqq CM, Scher HI, de Bono JS. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol. 2012;13(12):1210–1217. doi: 10.1016/S1470-2045(12)70473-4. PubMed DOI

Ueda Y, Matsubara N, Tabata KI, Satoh T, Kamiya N, Suzuki H, Kawahara T, Uemura H. Prostate-specific antigen flare phenomenon induced by abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2017;15(2):320–325. doi: 10.1016/j.clgc.2016.07.026. PubMed DOI

Madueke I, Lee RJ, Miyamoto DT. Circulating tumor cells and circulating tumor DNA in urologic cancers. Urol Clin North Am. 2023;50(1):109–114. doi: 10.1016/j.ucl.2022.09.010. PubMed DOI

Trujillo B, Wu A, Wetterskog D, Attard G. Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges. Br J Cancer. 2022;127(8):1394–1402. doi: 10.1038/s41416-022-01881-9. PubMed DOI PMC

Tulpule V, Morrison GJ, Falcone M, Quinn DI, Goldkorn A. Integration of liquid biopsies in clinical management of metastatic prostate cancer. Curr Oncol Rep. 2022;24(10):1287–1298. doi: 10.1007/s11912-022-01278-0. PubMed DOI PMC

Cieślikowski WA, Antczak A, Nowicki M, Zabel M, Budna-Tukan J. Clinical relevance of circulating tumor cells in prostate cancer management. Biomedicines. 2021;9(9):1179. doi: 10.3390/biomedicines9091179. PubMed DOI PMC